{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:19:15Z","timestamp":1790615955109,"version":"4.1.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100001234","name":"Robert and Janice McNair Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001234","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008527","name":"Dan L. Duncan Cancer Center, Baylor College of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008527","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005731","name":"Juntendo University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.jcyt.2020.04.098","type":"journal-article","created":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T00:34:14Z","timestamp":1588898054000},"page":"642-652","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Identification of protective T-cell antigens for smallpox vaccines"],"prefix":"10.1016","volume":"22","author":[{"given":"Jun","family":"Ando","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minhtran C.","family":"Ngo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miki","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Leen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cliona M.","family":"Rooney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2020.04.098_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2009.06.006","article-title":"Vaccinia virus vaccines: past, present and future","volume":"84","author":"Jacobs","year":"2009","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jcyt.2020.04.098_bib0002","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1093\/clinids\/4.5.916","article-title":"A successful eradication campaign. Global eradication of smallpox","volume":"4","author":"Fenner","year":"1982","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.jcyt.2020.04.098_bib0003","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/TME.0000000000000034","article-title":"Being prepared: bioterrorism and mass prophylaxis: part II","volume":"36","author":"Weant","year":"2014","journal-title":"Adv Emerg Nurs J"},{"key":"10.1016\/j.jcyt.2020.04.098_bib0004","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1586\/erv.09.55","article-title":"The new ACAM2000 vaccine and other therapies to control orthopoxvirus outbreaks and bioterror attacks","volume":"8","author":"Handley","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.jcyt.2020.04.098_bib0005","doi-asserted-by":"crossref","first-page":"959","DOI":"10.3201\/eid0706.010607","article-title":"Modeling potential responses to smallpox as a bioterrorist weapon","volume":"7","author":"Meltzer","year":"2001","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jcyt.2020.04.098_bib0006","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3201\/eid1902.121220","article-title":"Phylogenetic and ecologic perspectives of a monkeypox outbreak, southern Sudan, 2005","volume":"19","author":"Nakazawa","year":"2013","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jcyt.2020.04.098_bib0007","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1056\/NEJMc060792","article-title":"Discovery of monkeypox in Sudan","volume":"355","author":"Damon","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2020.04.098_bib0008","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1086\/512161","article-title":"Immunological memory after exposure to variola virus, monkeypox virus, and vaccinia virus","volume":"195","author":"Sivapalasingam","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jcyt.2020.04.098_bib0009","doi-asserted-by":"crossref","first-page":"920","DOI":"10.3201\/eid0706.010602","article-title":"Developing new smallpox vaccines","volume":"7","author":"Rosenthal","year":"2001","journal-title":"Emerg Infect Dis"},{"issue":"suppl 3","key":"10.1016\/j.jcyt.2020.04.098_bib0010","doi-asserted-by":"crossref","first-page":"S157","DOI":"10.1086\/524751","article-title":"US Civilian Smallpox Preparedness and Response Program, 2003","volume":"46","author":"Strikas","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcyt.2020.04.098_bib0011","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/infdis\/jis753","article-title":"Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia ankara as a smallpox vaccine in HIV-infected subjects","volume":"207","author":"Greenberg","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jcyt.2020.04.098_bib0012","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1006\/viro.1998.9123","article-title":"The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses","volume":"244","author":"Antoine","year":"1998","journal-title":"Virology"},{"key":"10.1016\/j.jcyt.2020.04.098_bib0013","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1099\/0022-1317-72-5-1031","article-title":"Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence","volume":"72","author":"Meyer","year":"1991","journal-title":"J Gen Virol"},{"key":"10.1016\/j.jcyt.2020.04.098_bib0014","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.virol.2005.06.002","article-title":"Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model","volume":"339","author":"Meseda","year":"2005","journal-title":"Virology"},{"key":"10.1016\/j.jcyt.2020.04.098_bib0015","doi-asserted-by":"crossref","first-page":"4590","DOI":"10.1073\/pnas.0401165101","article-title":"Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge","volume":"101","author":"Wyatt","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"10.1016\/j.jcyt.2020.04.098_bib0016","doi-asserted-by":"crossref","first-page":"4825","DOI":"10.1073\/pnas.89.11.4825","article-title":"The E3L gene of vaccinia virus encodes an inhibitor of the interferon-induced, double-stranded RNA-dependent protein kinase","volume":"89","author":"Chang","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jcyt.2020.04.098_bib0017","doi-asserted-by":"crossref","first-page":"9684","DOI":"10.1016\/j.vaccine.2011.09.135","article-title":"Attenuated NYCBH vaccinia virus deleted for the E3L gene confers partial protection against lethal monkeypox virus disease in cynomolgus macaques","volume":"29","author":"Denzler","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.jcyt.2020.04.098_bib0018","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1073\/pnas.0711573105","article-title":"Kinetic analysis of a complete poxvirus transcriptome reveals an immediate-early class of genes","volume":"105","author":"Assarsson","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jcyt.2020.04.098_bib0019","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/CJI.0b013e3181c0c3cb","article-title":"Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex)","volume":"33","author":"Vera","year":"2010","journal-title":"J Immunother"},{"key":"10.1016\/j.jcyt.2020.04.098_bib0020","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1002\/eji.1830271209","article-title":"Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions","volume":"27","author":"Jonuleit","year":"1997","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jcyt.2020.04.098_bib0021","doi-asserted-by":"crossref","unstructured":"Bollard CM, Huls MH, Buza E, Weiss H, Torrano V, Gresik MV, et\u00a0al. Administration of latent membrane protein 2-specific cytotoxic T lymphocytes to patients with relapsed Epstein-Barr virus-positive lymphoma. Clin Lymphoma Myeloma 2006;6:342-7.","DOI":"10.3816\/CLM.2006.n.011"},{"key":"10.1016\/j.jcyt.2020.04.098_bib0022","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1002\/1521-4141(200006)30:6<1676::AID-IMMU1676>3.0.CO;2-V","article-title":"Analysis of CD8 T cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides","volume":"30","author":"Kern","year":"2000","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jcyt.2020.04.098_bib0023","doi-asserted-by":"crossref","DOI":"10.3791\/2736","article-title":"Generation of multivirus-specific T cells to prevent\/treat viral infections after allogeneic hematopoietic stem cell transplant","author":"Gerdemann","year":"2011","journal-title":"J Vis Exp"},{"key":"10.1016\/j.jcyt.2020.04.098_bib0024","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/CJI.0000000000000014","article-title":"Complementation of antigen-presenting cells to generate T lymphocytes with broad target specificity","volume":"37","author":"Ngo","year":"2014","journal-title":"J Immunother"},{"key":"10.1016\/j.jcyt.2020.04.098_bib0025","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1007\/BF02619631","article-title":"Use of cyclosporin A in establishing Epstein-Barr virus-transformed human lymphoblastoid cell lines","volume":"20","author":"Anderson","year":"1984","journal-title":"In Vitro"},{"key":"10.1016\/j.jcyt.2020.04.098_bib0026","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1084\/jem.138.6.1398","article-title":"Comparison of the yield of infectious virus from clones of human and simian lymphoblastoid lines transformed by Epstein-Barr virus","volume":"138","author":"Miller","year":"1973","journal-title":"J Exp Med"},{"key":"10.1016\/j.jcyt.2020.04.098_bib0027","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1089\/scd.1.1995.4.73","article-title":"Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease","volume":"4","author":"Smith","year":"1995","journal-title":"J Hematother"},{"key":"10.1016\/j.jcyt.2020.04.098_bib0028","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.virol.2006.08.025","article-title":"Protein composition of the vaccinia virus mature virion","volume":"358","author":"Resch","year":"2007","journal-title":"Virology"},{"issue":"Pt 9","key":"10.1016\/j.jcyt.2020.04.098_bib0029","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1099\/0022-1317-76-9-2393","article-title":"Vaccinia virus serpins B13R and B22R do not inhibit antigen presentation to class I-restricted cytotoxic T lymphocytes","volume":"76","author":"Blake","year":"1995","journal-title":"J Gen Virol"},{"key":"10.1016\/j.jcyt.2020.04.098_bib0030","doi-asserted-by":"crossref","first-page":"10238","DOI":"10.1128\/JVI.78.19.10238-10248.2004","article-title":"Vaccinia virus mutants with alanine substitutions in the conserved G5R gene fail to initiate morphogenesis at the nonpermissive temperature","volume":"78","author":"da Fonseca","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.jcyt.2020.04.098_bib0031","doi-asserted-by":"crossref","first-page":"10627","DOI":"10.1128\/JVI.01260-09","article-title":"Vaccinia virus K1L and C7L inhibit antiviral activities induced by type I interferons","volume":"83","author":"Meng","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.jcyt.2020.04.098_bib0032","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/0042-6822(90)90296-4","article-title":"Vaccinia virus host range genes","volume":"179","author":"Perkus","year":"1990","journal-title":"Virology"},{"issue":"13","key":"10.1016\/j.jcyt.2020.04.098_bib0033","doi-asserted-by":"crossref","first-page":"5778","DOI":"10.1128\/JVI.75.13.5778-5795.2001","article-title":"The major core protein P4a (A10L gene) of vaccinia virus is essential for correct assembly of viral DNA into the nucleoprotein complex to form immature viral particles","volume":"75","author":"Heljasvaara","year":"2001","journal-title":"J Virol"},{"key":"10.1016\/j.jcyt.2020.04.098_bib0034","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1128\/jvi.6.6.717-726.1970","article-title":"Vaccinia virus structural polypeptide derived from a high-molecular-weight precursor: formation and integration into virus particles","volume":"6","author":"Katz","year":"1970","journal-title":"J Virol"},{"key":"10.1016\/j.jcyt.2020.04.098_bib0035","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1128\/JVI.74.7.3353-3365.2000","article-title":"Vaccinia virus envelope H3L protein binds to cell surface heparan sulfate and is important for intracellular mature virion morphogenesis and virus infection in vitro and in vivo","volume":"74","author":"Lin","year":"2000","journal-title":"J Virol"},{"key":"10.1016\/j.jcyt.2020.04.098_bib0036","doi-asserted-by":"crossref","first-page":"e60420","DOI":"10.1371\/journal.pone.0060420","article-title":"High efficiency of antiviral CD4(+) killer T cells","volume":"8","author":"Hildemann","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jcyt.2020.04.098_bib0037","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1089\/jir.2009.0073","article-title":"The interferon system and vaccinia virus evasion mechanisms","volume":"29","author":"Perdiguero","year":"2009","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.jcyt.2020.04.098_bib0038","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1084\/jem.168.4.1211","article-title":"Defective presentation to class I-restricted cytotoxic T lymphocytes in vaccinia-infected cells is overcome by enhanced degradation of antigen","volume":"168","author":"Townsend","year":"1988","journal-title":"J Exp Med"},{"key":"10.1016\/j.jcyt.2020.04.098_bib0039","first-page":"203","article-title":"Window of vulnerability of vaccinia virus-infected cells to natural killer (NK) cell-mediated cytolysis correlates with enhanced NK cell triggering and is concomitant with a decrease in H-2 class I antigen expression","volume":"11","author":"Brutkiewicz","year":"1992","journal-title":"Nat Immun"},{"key":"10.1016\/j.jcyt.2020.04.098_bib0040","doi-asserted-by":"crossref","first-page":"6481","DOI":"10.4049\/jimmunol.175.10.6481","article-title":"Disruption of MHC class II-restricted antigen presentation by vaccinia virus","volume":"175","author":"Li","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.jcyt.2020.04.098_bib0041","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.cellimm.2007.06.005","article-title":"Vaccinia virus infection induces dendritic cell maturation but inhibits antigen presentation by MHC class II","volume":"246","author":"Yao","year":"2007","journal-title":"Cell Immunol"},{"key":"10.1016\/j.jcyt.2020.04.098_bib0042","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1365-2567.2009.03120.x","article-title":"Vaccinia virus decreases major histocompatibility complex (MHC) class II antigen presentation, T-cell priming, and peptide association with MHC class II","volume":"128","author":"Rehm","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.jcyt.2020.04.098_bib0043","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1073\/pnas.0409846102","article-title":"Vaccinia viruses with a serpin gene deletion and expressing IFN-gamma induce potent immune responses without detectable replication in vivo","volume":"102","author":"Legrand","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jcyt.2020.04.098_bib0044","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1128\/JVI.02042-08","article-title":"Gamma interferon-induced interferon regulatory factor 1-dependent antiviral response inhibits vaccinia virus replication in mouse but not human fibroblasts","volume":"83","author":"Trilling","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.jcyt.2020.04.098_bib0045","doi-asserted-by":"crossref","first-page":"G21","DOI":"10.1016\/j.vaccine.2009.10.011","article-title":"Definition of epitopes and antigens recognized by vaccinia specific immune responses: their conservation in variola virus sequences, and use as a model system to study complex pathogens","volume":"27","author":"Sette","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.jcyt.2020.04.098_bib0046","doi-asserted-by":"crossref","first-page":"13980","DOI":"10.1073\/pnas.0506768102","article-title":"HLA class I-restricted responses to vaccinia recognize a broad array of proteins mainly involved in virulence and viral gene regulation","volume":"102","author":"Oseroff","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jcyt.2020.04.098_bib0047","doi-asserted-by":"crossref","first-page":"6757","DOI":"10.1128\/JVI.02570-08","article-title":"Vaccinia virus E3 suppresses expression of diverse cytokines through inhibition of the PKR, NF-kappaB, and IRF3 pathways","volume":"83","author":"Myskiw","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.jcyt.2020.04.098_bib0048","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1006\/viro.1998.9072","article-title":"Vaccinia virus E3L protein is an inhibitor of the interferon (i.f.n.)-induced 2-5A synthetase enzyme","volume":"243","author":"Rivas","year":"1998","journal-title":"Virology"},{"key":"10.1016\/j.jcyt.2020.04.098_bib0049","doi-asserted-by":"crossref","first-page":"7659","DOI":"10.1016\/j.vaccine.2011.07.140","article-title":"The NYCBH vaccinia virus deleted for the innate immune evasion gene, E3L, protects rabbits against lethal challenge by rabbitpox virus","volume":"29","author":"Denzler","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.jcyt.2020.04.098_bib0050","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1016\/j.vaccine.2008.03.044","article-title":"Vaccinia viruses with mutations in the E3L gene as potential replication-competent, attenuated vaccines: scarification vaccination","volume":"26","author":"Jentarra","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.jcyt.2020.04.098_bib0051","doi-asserted-by":"crossref","first-page":"9691","DOI":"10.1016\/j.vaccine.2011.09.108","article-title":"The attenuated NYCBH vaccinia virus deleted for the immune evasion gene, E3L, completely protects mice against heterologous challenge with ectromelia virus","volume":"29","author":"Denzler","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.jcyt.2020.04.098_bib0052","doi-asserted-by":"crossref","first-page":"8743","DOI":"10.1128\/JVI.00604-10","article-title":"Immediate-early expression of a recombinant antigen by modified vaccinia virus ankara breaks the immunodominance of strong vector-specific B8R antigen in acute and memory CD8 T-cell responses","volume":"84","author":"Baur","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.jcyt.2020.04.098_bib0053","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.vaccine.2009.11.030","article-title":"A randomized, double-blind, dose-finding phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE","volume":"28","author":"von Krempelhuber","year":"2010","journal-title":"Vaccine"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324920306551?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324920306551?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T01:41:18Z","timestamp":1761442878000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324920306551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":53,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S1465324920306551"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2020.04.098","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of protective T-cell antigens for smallpox vaccines","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2020.04.098","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 International Society for Cell &#38; Gene Therapy. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}